Founded in 2019 and based in Hong Kong, GenieBiome is a biotechnology spinout from The Chinese University of Hong Kong. Their team of clinician-scientists and experts in microbiology, metagenomics, bioinformatics, and clinical trials has been pioneering the use of microbiome to tackle diseases such as COVID-19, colorectal cancer, obesity, eczema, and autism. Their precision portfolio, G-NiiB, includes diagnostic and risk prediction tests, next-generation microbiome precision formulas, and precision medicine tailored for the Asian population.